

COL17A1 RABBIT PAB

货号: S221760

产品全名: COL17A1 兔多抗

基因符号: ERED; BP180; BPA-2; BPAG2; LAD-1; BA16H23.2

UNIPROT ID: Q9UMD9 (Gene Accession - NP_000485)

背景: This gene encodes the alpha chain of type XVII collagen. Unlike most collagens, collagen XVII is a transmembrane protein. Collagen XVII is a structural component of hemidesmosomes, multiprotein complexes at the dermal-epidermal basement membrane zone that mediate adhesion of keratinocytes to the underlying membrane. Mutations in this gene are associated with both generalized atrophic benign and junctional epidermolysis bullosa. Two homotrimeric forms of type XVII collagen exist. The full length form is the transmembrane protein. A soluble form, referred to as either ectodomain or LAD-1, is generated by proteolytic processing of the full length form.

抗原: Synthetic peptide of human COL17A1

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 50-200; ELISA: 5000-10000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human, Mouse


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Signal Transduction


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human colorectal cancer tissue using 221760(COL17A1 Antibody) at a dilution of 1/50(Cytoplasm).



In comparison with the IHC on the left, the same paraffin-embedded Human colorectal cancer tissue is first treated with the synthetic peptide and then with 221760(Anti-COL17A1 Antibody) at dilution 1/50.



The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using 221760(Anti-COL17A1 Antibody) at a dilution of 1/50.



In comparison with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with synthetic peptide and then with D263493(Anti-COL17A1 Antibody) at dilution 1/50.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
